How should heart wall thickening be evaluated and managed?

Heart Wall Thickening: Evaluation and Management

When you detect heart wall thickening, immediately measure the maximal left ventricular wall thickness using echocardiography or cardiac MRI, and systematically exclude loading conditions (hypertension, aortic stenosis) before pursuing a diagnosis of hypertrophic cardiomyopathy or its mimics.

Diagnostic Thresholds

In adults, hypertrophic cardiomyopathy (HCM) is defined by LV wall thickness ≥15 mm in any segment that cannot be explained by loading conditions 1. However, lesser degrees of thickening (13-14 mm) warrant HCM diagnosis when accompanied by:

• Family history of HCM
• Pathogenic/likely pathogenic genetic variant
• Abnormal ECG findings
• Characteristic imaging features 1

In children, HCM requires LV wall thickness >2 standard deviations above the predicted mean (z-score >2.5, or >2.0 with family history or genetic variant) 2.

For first-degree relatives of HCM patients, the diagnostic threshold is lower at ≥13 mm of unexplained wall thickening 1.

Systematic Evaluation Algorithm

Step 1: Confirm and Quantify Wall Thickening

• Use echocardiography as first-line imaging (readily available, cost-effective)
• Add cardiac MRI when:
  • Echocardiographic windows are inadequate
  • Wall thickness measurements are borderline (13-15 mm)
  • You need to assess for myocardial fibrosis, apical involvement, or differential diagnosis 1

Important caveat: Echocardiography and MRI can differ significantly in maximal wall thickness measurements—discrepancies up to 17 mm have been reported, with MRI typically measuring thicker walls 3. This matters critically when deciding on implantable cardioverter-defibrillator placement for massive hypertrophy (≥30 mm).

Step 2: Exclude Loading Conditions

Before diagnosing HCM, rule out:

• Hypertension: Severe hypertension with mild symmetric hypertrophy favors hypertensive heart disease; mild hypertension with asymmetric or severe wall thickening (>18 mm) favors HCM 2
• Aortic stenosis
• Athletic training ("athlete's heart")—typically shows wall thickness 13-15 mm with normal diastolic function and resolves with deconditioning 1, 4

Step 3: Search for HCM Mimics

Critical distinction: Many conditions can mimic HCM but require entirely different treatments. Look for these red flags:

Cardiac Amyloidosis (especially ATTR):

• Relative wall thickness (RWT) >0.72 is highly suggestive (RWT = 2 × posterior wall thickness / LV end-diastolic diameter) 5
• Small LV cavity despite thick walls
• Biatrial enlargement
• Low voltage on ECG despite thick walls
• Confirm with 99mTc-pyrophosphate scintigraphy 5

Fabry Disease:

• Look for extracardiac manifestations: angiokeratomas, corneal verticillata, renal dysfunction, neuropathic pain
• Check alpha-galactosidase A levels
• Enzyme replacement therapy is available 1

Endocrine Disorders:

• Acromegaly: Check IGF-1 levels; hypertrophy resolves with treatment 1
• Pheochromocytoma: Check plasma metanephrines; hypertrophy resolves with treatment 1

Drug-Induced:

• Chronic use of anabolic steroids, tacrolimus, hydroxychloroquine (rarely causes wall thickness ≥15 mm) 1

Metabolic/Storage Diseases:

• Pompe disease, Danon disease (LAMP2 mutations), PRKAG2 mutations
• Consider in young patients or those with multisystem involvement 1, 4

Step 4: Complete the Diagnostic Workup

Mandatory tests for all patients with unexplained LV hypertrophy:

• 12-lead ECG: Look for LV hypertrophy pattern, deep T-wave inversions (especially in apical HCM), Q waves
• Comprehensive echocardiography: Assess wall thickness in all segments, LV outflow tract gradient (rest and Valsalva), systolic anterior motion, mitral valve abnormalities, diastolic function 1
• Laboratory: Thyroid function, renal function, hepatic function 6
• Family history: Three-generation pedigree focusing on HCM, sudden cardiac death <50 years, heart failure 1

Consider genetic testing when:

• Diagnostic criteria for HCM are met (enables cascade screening of relatives) 1
• Wall thickness is borderline (13-14 mm) with other suggestive features
• Differentiating between HCM and phenocopies 1

Add cardiac MRI when:

• Assessing for late gadolinium enhancement (≥15% of LV mass increases sudden death risk) 7, 8
• Detecting apical aneurysm (high-risk feature)
• Evaluating apical HCM (often missed on echocardiography)
• Quantifying fibrosis burden 1

Common Diagnostic Pitfalls

1. Isolated basal septal hypertrophy in elderly patients with hypertension (sigmoid septum) may not represent true HCM 1, 2

2. Apical HCM can present with relative hypertrophy (apex <15 mm but apex:base ratio >1) with marked precordial T-wave inversions—don't miss this variant 2

3. End-stage HCM presents with LV dilation, systolic dysfunction, and wall thinning—requires high index of suspicion and family history 1

4. Genotype-positive/phenotype-negative individuals have the genetic mutation but no wall thickening yet—they don't have clinical HCM but need surveillance 7

Management Priorities Based on Etiology

If HCM is confirmed:

• Risk stratify for sudden cardiac death using established risk factors (massive hypertrophy ≥30 mm, family history of sudden death, unexplained syncope, nonsustained VT, extensive LGE, apical aneurysm, systolic dysfunction) 7, 8
• Manage symptoms and obstruction
• Screen first-degree relatives
• Genetic counseling

If a treatable mimic is identified:

• ATTR amyloidosis: Tafamidis or other disease-modifying therapy
• Fabry disease: Enzyme replacement therapy
• Endocrine disorders: Treat underlying condition; hypertrophy typically regresses 1
• Drug-induced: Discontinue offending agent

The key to optimal outcomes is recognizing that not all wall thickening is HCM—systematic evaluation prevents missed diagnoses of treatable conditions and ensures appropriate risk stratification when HCM is confirmed.